|
SU added at index
|
80.8%
|
73.6%
|
0.003
|
-
|
-
|
-
|
|
Glitazones added at index
|
19.2%
|
26.4%
| |
-
|
-
|
-
|
|
Demographics
| | | | | | |
|
Age (years)
|
64.3 (9.2)
|
59.5 (10.5)
|
< 0.0001
|
64.0 (9.0)
|
63.9 (10.1)
|
0.96
|
|
Male
|
65.5%
|
51.3%
|
< 0.0001
|
65.0%
|
70.3%
|
0.11
|
|
Caucasian
|
98.0%
|
96.7%
|
0.17
|
98.0%
|
98.4%
|
0.68
|
|
Duration of diabetes (years)
|
6.1 (5.2)
|
5.6 (4.8)
|
0.09
|
6.0 (5.0)
|
6.1 (5.0)
|
0.99
|
|
Never used alcohol
|
27.6%
|
30.4%
|
0.29
|
27.9%
|
26.1%
|
0.57
|
|
Physical Activity
| | | | | | |
|
No regular activity
|
39.1%
|
34.6%
|
0.11
|
37.6%
|
39.5%
|
0.58
|
|
< 3 times/week
|
39.1%
|
39.7%
|
0.83
|
41.0%
|
36.5%
|
0.12
|
|
≥ 3 times/week
|
21.9%
|
25.7%
|
0.12
|
21.4%
|
24.0%
|
0.34
|
|
Country
| | | | | | |
|
Spain
|
15.8%
|
28.1%
|
< 0.0001
|
16.2%
|
15.0%
|
0.62
|
|
France
|
6.9%
|
8.1%
|
0.43
|
7.1%
|
6.9%
|
0.89
|
|
UK
|
26.6%
|
16.9%
|
< 0.0001
|
26.7%
|
26.4%
|
0.94
|
|
Norway
|
3.0%
|
3.4%
|
0.67
|
3.1%
|
4.8%
|
0.20
|
|
Finland
|
7.4%
|
10.7%
|
0.049
|
7.6%
|
10.2%
|
0.21
|
|
Germany
|
17.7%
|
21.4%
|
0.10
|
18.3%
|
19.8%
|
0.59
|
|
Poland
|
22.7%
|
11.5%
|
< 0.0001
|
21.1%
|
17.0%
|
0.15
|
|
Baseline Clinical Information
| | | | | | |
|
HbA1c (%)
|
8.1 (1.3)
|
8.0 (1.4)
|
0.69
|
8.06 (1.26)
|
8.05 (1.39)
|
0.96
|
|
With HbA1c < 6.5%
|
5.2%
|
8.3%
|
0.037
|
5.1%
|
7.6%
|
0.14
|
|
Body mass index (kg/m2)
|
31.7 (8.2)
|
31.9 (6.2)
|
0.60
|
31.7 (6.6)
|
31.7 (6.7)
|
0.94
|
|
Physician specialty
| | | | | | |
|
Endocrinologists/Diabetologists
|
40.6%
|
40.6%
|
0.99
|
40.6%
|
41.1%
|
0.89
|
|
General practitioners/Internists
|
59.4%
|
59.4%
| |
59.4%
|
58.9%
| |
|
Duration of metformin use (years)
|
3.0 (2.9)
|
2.8 (2.5)
|
0.15
|
2.9 (2.7)
|
2.8 (2.5)
|
0.60
|
